receive Seven Year Quarterly Royalty Payment Stream from Pfizer
Aptevo Therapeutics to receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimilar.
it will receive a royalty from Pfizer related to sales of a rituximab biosimilar product, RUXIENCE® (Rituximab-pvvr), which was approved by the U.S. Food and Drug Administration in July 2019 and launched by Pfizer in the United States and Japan in early 2020.
This funding will help to support the advancement of our novel ADAPTIR™ bispecific antibody platform and more specifically, our lead ADAPTIR bispecific candidate, APVO436, which is progressing in a Phase 1/1b clinical study for the treatment of acute myeloid leukemia. Dosing in cohort 6 of the study is currently underway. We look forward to providing an update on this clinical program as additional data are available."
Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year
Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSolutions
it will receive a royalty from Pfizer related to sales of a rituximab biosimilar product, RUXIENCE® (Rituximab-pvvr), which was approved by the U.S. Food and Drug Administration in July 2019 and launched by Pfizer in the United States and Japan in early 2020.
This funding will help to support the advancement of our novel ADAPTIR™ bispecific antibody platform and more specifically, our lead ADAPTIR bispecific candidate, APVO436, which is progressing in a Phase 1/1b clinical study for the treatment of acute myeloid leukemia. Dosing in cohort 6 of the study is currently underway. We look forward to providing an update on this clinical program as additional data are available."
Published Articles Suggest the Global Market for Rituximab Biosimilars Could Potentially be over $1 Billion Per Year
Royalty Stream Relates to Agreement Acquired in Aptevo Spin-off from Emergent BioSolutions